|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-5-17
|
|
pubmed:abstractText |
The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3915-24
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15897593-Anemia,
pubmed-meshheading:15897593-Animals,
pubmed-meshheading:15897593-Antibiotics, Antineoplastic,
pubmed-meshheading:15897593-Antineoplastic Agents,
pubmed-meshheading:15897593-Cardiovascular Agents,
pubmed-meshheading:15897593-Cell Culture Techniques,
pubmed-meshheading:15897593-Colony-Forming Units Assay,
pubmed-meshheading:15897593-Daunorubicin,
pubmed-meshheading:15897593-Doxorubicin,
pubmed-meshheading:15897593-Etoposide,
pubmed-meshheading:15897593-Female,
pubmed-meshheading:15897593-Leukopenia,
pubmed-meshheading:15897593-Mice,
pubmed-meshheading:15897593-Neutropenia,
pubmed-meshheading:15897593-Razoxane,
pubmed-meshheading:15897593-Thrombocytopenia
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
|
|
pubmed:affiliation |
Laboratory of Experimental Medical Oncology, Finsen Center, Copenhagen, Denmark. kfh@topotarget.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
